Sandoz Sues Watson, Amphastar Over Generic Lovenox

Law360, New York (September 23, 2011, 1:25 PM EDT) -- Sandoz Inc. and Momenta Pharmaceuticals Inc. on Wednesday filed a patent suit in Massachusetts against Watson Pharmaceuticals Inc. and Amphastar Pharmaceuticals Inc., aiming to block the launch of a recently approved competing generic version of Sanofi-Aventis SA's anticoagulant Lovenox.

Patent owner Momenta and exclusive licensee Sandoz targeted Watson, Amphastar and Amphastar unit International Medication Systems Ltd., seeking “up to treble damages” as well as preliminary and permanent injunctions. The complaint accuses Amphastar and IMS of making their generic using methods covered by the patents-in-suit.

“Watson and...
To view the full article, register now.